Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 9/20 | 0.58 |
| ▸ | CPT1A | P50416 | 4/20 | 0.57 |
| ▸ | CPT2 | P23786 | 3/20 | 0.57 |
| ▸ | CPT1B | Q92523 | 3/20 | 0.53 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.52 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.52 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.52 |
| ▸ | PPARG | P37231 | 3/20 | 0.50 |
| ▸ | PPARD | Q03181 | 2/20 | 0.50 |
| ▸ | PPARA | Q07869 | 2/20 | 0.50 |
| ▸ | FABP4 | P15090 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22074272 | 0.90 | HTR6 (0.60) | HTR6CPT1ACPT2CPT1BPPARG | |
| SCHEMBL22980669 | 0.85 | HTR6 (0.78) | HTR6CPT1ACPT2CPT1BSLC1A3 | |
| SCHEMBL22990912 | 0.85 | HTR6 (0.51) | HTR6CPT1ACPT2CPT1BSLC1A3 | |
| SCHEMBL28933624 | 0.84 | HTR6 (0.64) | HTR6CPT1ACPT2CPT1BSLC1A3 | |
| SCHEMBL1898211 | 0.82 | HTR6 (0.56) | HTR6SLC1A3SLC1A2SLC1A1PPARG | |
| SCHEMBL8652798 | 0.82 | CPT1A (0.63) | HTR6CPT1ACPT2CPT1BSLC1A3 | |
| SCHEMBL20742946 | 0.79 | HTR6 (0.60) | HTR6PPARGPPARDPPARAFABP4 | |
| SCHEMBL9372377 | 0.79 | CPT1A (0.54) | HTR6CPT1ACPT2CPT1BSLC1A3 | |
| SCHEMBL30955477 | 0.79 | CPT1A (0.54) | HTR6CPT1ACPT2CPT1BSLC1A3 | |
| SCHEMBL17049351 | 0.78 | PPARG (0.53) | HTR6CPT1ACPT2PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4010080-B1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LTD (GB) | 2023-09-27 | — | — | EP | disclosed |
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2023-08-03 | — | — | US | disclosed |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2022-09-22 | — | — | US | disclosed |
| EP-4010080-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | Artios Pharma Limited (GB) | 2022-06-15 | — | — | EP | disclosed |
| WO-2021028643-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | ARTIOS PHARMA LIMITED (GB) | 2021-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242503-A9 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | HTR6 3126/4885CPT1A 209/4885CPT2 501/4885 |
| US-20220298134-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF CANCER | SDHA, SDHB, NQO1 | HTR6 3126/4885CPT1A 209/4885CPT2 501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.